A Phase 3 interventional study of Ozenoxacin and Placebo in Impetigo, sponsored by Ferrer Internacional S.A.. Completed at 1 site in Puerto Rico. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2024-08-20.
Sponsored by Ferrer Internacional S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is multicenter, randomised, placebo controlled, parallel, double blinded , superiority clinical study comparing ozenoxacin cream versus placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.
30 studies on the registry are indexed under Impetigo; 3 are open to participants now.
This study's enrollment of 412 is above the median of 255 across 24 interventional studies indexed under Impetigo.
Browse Impetigo studies →Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ozenoxacin cream 1%
Drug: Ozenoxacin
Placebo cream
Drug: Placebo
Clinical Success
Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population. Clinical success at V3 was defined as: SIRS score 0 for blistering, exudates/pus, crusting and itching/pain and no more than 1 for erythema/inflammation such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary. The skin infection rating scale (SIRS) is a severity index based on five signs or symptoms: blistering, exudate/pus, crusting, erythema/inflammation, itching/pain.
Time frame: Visit 3 (Day 6-7)
Patients were enrolled at 34 sites in Germany, Puerto Rico, Romania, Russia, South Africa, Spain and the United States of America (USA).
| Milestone | Ozenoxacin | Placebo |
|---|---|---|
| Started | 206 | 206 |
| Completed | 200 | 186 |
| Not completed | 6 | 20 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 13 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Intercurrent illness and other | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
Clinical response (clinical success or clinical failure) at end of therapy (Visit 3) in the intent to treat clinical (ITTC) population. Clinical success at V3 was defined as: SIRS score 0 for blistering, exudates/pus, crusting and itching/pain and no more than 1 for erythema/inflammation such that no additional antimicrobial therapy in the baseline (Visit 1) affected area is necessary. The skin infection rating scale (SIRS) is a severity index based on five signs or symptoms: blistering, exudate/pus, crusting, erythema/inflammation, itching/pain.
| percentage of Participants | Ozenoxacin | Placebo |
|---|---|---|
| Clinical Success | 55.2 | 39.2 |
Collected over AEs were elicited from signing the informed consent to the completion of the clinical study (including the Follow up Visit) or premature patient withdrawal from the study. (10-13 days). Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ozenoxacin | — | 0/206 (0%) | 0/206 (0%) |
| Placebo | — | 0/205 (0%) | 0/205 (0%) |
Baseline analysis population was consider the safety population. Safety population was defined as all patients who received at least one application of study drug. One patient was randomised to placebo but never treated.
| Age, Customized(participants) | Ozenoxacin | Placebo | Total |
|---|---|---|---|
| >=18 years | 69 | 70 | 139 |
| >=12 years to <18 years | 23 | 23 | 46 |
| >= 2 months to <12 years | 114 | 112 | 226 |
| Sex: Female, Male(Participants) | Ozenoxacin | Placebo | Total |
|---|---|---|---|
| Female | 94 | 107 | 201 |
| Male | 112 | 98 | 210 |
| Race/Ethnicity, Customized(participants) | Ozenoxacin | Placebo | Total |
|---|---|---|---|
| Caucasian | 122 | 139 | 261 |
| Black | 53 | 38 | 91 |
| Asian | 16 | 15 | 31 |
| Mixed Race | 15 | 13 | 28 |
| Region of Enrollment(participants) | Ozenoxacin | Placebo | Total |
|---|---|---|---|
| Puerto Rico | 23 | 23 | 46 |
| Germany | 21 | 16 | 37 |
| Romania | 26 | 26 | 52 |
| Russian Federation | 27 | 30 | 57 |
| South Africa | 43 | 34 | 77 |
| Spain | 1 | 2 | 3 |
| United States | 65 | 74 | 139 |
The record gives a start of Jun 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ozenoxacin